SCHEMBL1035454

SCHEMBL1035454

C=COC(=O)CP(C(=O)c1c(C)cc(C)cc1C)C(=O)c1c(C)cc(C)cc1C

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CRHR1 P34998 1/20 0.33
KMT2A Q03164 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
NLRP3 Q96P20 1/20 0.31
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15636005 0.85 KDM4E (0.33) KDM4EL3MBTL1CRHR1KMT2ASMN1; SMN2
SCHEMBL1035817 0.81 KDM4E (0.37) KDM4EL3MBTL1KMT2ASMN1; SMN2MEN1
SCHEMBL1034451 0.80 NLRP3 (0.45) KDM4EL3MBTL1KMT2ASMN1; SMN2MEN1
SCHEMBL13412090 0.77 KDM4E (0.41) KDM4EL3MBTL1KMT2ASMN1; SMN2MEN1
SCHEMBL1034997 0.75 KDM4E (0.40) KDM4EL3MBTL1KMT2ASMN1; SMN2MEN1
SCHEMBL1035040 0.73 CRHR1 (0.38) KDM4EL3MBTL1CRHR1KMT2ASMN1; SMN2
SCHEMBL1036934 0.72 KDM4E (0.36) KDM4EL3MBTL1CRHR1KMT2ASMN1; SMN2
SCHEMBL9889294 0.72 CRHR1 (0.35) KDM4EL3MBTL1CRHR1KMT2ASMN1; SMN2
SCHEMBL1033190 0.71 NAAA (0.45) KMT2AMEN1LMNAALDH1A1
SCHEMBL16401942 0.71 NAAA (0.45) KMT2AMEN1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814891-B1 BISACYLPHOSPHANES AND THEIR USE AS PHOTOINITIATORS; PROCESS FOR PREPARING ACYLPHOSPHANES BASF SE (DE) 2011-01-26 EP disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 US disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 US disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 US disclosed
EP-1814891-A1 PROCESS FOR PREPARING ACYLPHOSPHANES AND DERIVATIVES THEREOF Ciba Specialty Chemicals Holding Inc. (CH) 2007-08-08 EP disclosed
WO-2006056541-A1 PROCESS FOR PREPARING ACYLPHOSPHANES AND DERIVATIVES THEREOF CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof ME2, ME3, MEP1A KDM4E 2950/4885L3MBTL1 1140/4885CRHR1 3831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.